Category Archives: RXDX-101 – entrectinib – by Ignyta

Entrectinib phase 1-2 trial update

Entrectinib was tested in 119 patients with three kinds of mutations: NTRK+, ALK, and ROS1. Efficacy data was reported for 24 patients. For ALK there appear to have been 5 patients, and 57% of them had a tumor response (presumably … Continue reading

Posted in Lung cancer, Potential Treatments, Research, RXDX-101 - entrectinib - by Ignyta, Side Effects | Leave a comment

Article on latest develpments

In January 2016 an article was published that reviewed the current status of nine 2nd generation and 3rd generation ALK inhibitors, some HSP 90 inhibitors and briefly 2 immunotherapies for lung cancer. Much of that research has been described in … Continue reading

Posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, ASP3026 from Astellas, CEP-37440, ceritinib - Zykadia from Novartis, Imunotherapies, Lung cancer, NMS-E628, Potential Treatments, Research, Resistance to treatment, RXDX-101 - entrectinib - by Ignyta, Side Effects, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery | Leave a comment

Ignyta announced results of phase 1 trial and start of phase 2 trial

As of September 30, 2015. Two Phase 1 results: Total of 92 patients 18 patients met phase 2 eligibility requirements and took phase 2 dose level Among 18 patients 72% respose rate. 4 of 6 (66%) ALK+ patients responded. Drug … Continue reading

Posted in Lung cancer, Research, RXDX-101 - entrectinib - by Ignyta, Side Effects | Leave a comment

ASCO links

Here are 18 ALK+ related abstract links related to the drugs listed below. On the ASCO website 77 abstracts refered to both “ALK” and “Inhibitor”.  When I get a chance I will write up a summary on some of the … Continue reading

Posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, ceritinib - Zykadia from Novartis, Lung cancer, Potential Treatments, Research, RXDX-101 - entrectinib - by Ignyta, Side Effects, TSR-011 from Tesaro | Leave a comment

Ignyta update

As of December 4, 2014, Ignyta has posted the following in a press release: “Entrectinib is currently in two Phase I/II clinical trials, the STARTRK-1 trial and the ALKA-372-001 trial. The company presented interim results from the ALKA-372-001 study in … Continue reading

Posted in Lung cancer, Neuroblastomas, RXDX-101 - entrectinib - by Ignyta | Leave a comment

Article by Dr. Shaw on current status of ALK Inhibitor drugs

Dr. Shaw has written a comprehensive article on all 10 ALK Inhibitors being developed as of July 7, 2014. It provides comparisons of testing status, concentration levels, side effects and much more. It also includes a 2 page list of … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, CEP-37440, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, NMS-E628, Potential Treatments, Regulatory applications & approvals, Research, Resistance to treatment, RXDX-101 - entrectinib - by Ignyta, Side Effects, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery | Leave a comment

List of 8 ALK Inhibitors in trials

List of 8 ALK inhibitor drugs currently in clinical trials: FDA approved (but several trials ongoing) Pfizer – Crizotinib (2011 initial, 2013 final) Novartis – Ceritinib (2014 initial) FDA Breakthrough Status Chugai – Alectinib (approved in Japan in 2014) Ariad … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, Regulatory applications & approvals, Research, RXDX-101 - entrectinib - by Ignyta, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery | Leave a comment

GRACE conference in Boston

There were several presentations as part of the Grace conference in Boston on Saturday, September 6. So far this is the only one I have found online. PowerPoint presentation by Dr. Alice Shaw on 8 or 9 new ALK inhibitors … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, NMS-E628, Potential Treatments, Research, Resistance to treatment, RXDX-101 - entrectinib - by Ignyta, Side Effects, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery | 1 Comment

Ignyta RXDX results

RXDX phase 1 partial results announced. Still dose escalating. 11 patients with ALK alterations had been dosed (seven of whom had received prior treatment with crizotinib), 11 patients with ROS1 alterations had been dosed, two patients with TrkA alterations had … Continue reading

Posted in RXDX-101 - entrectinib - by Ignyta | Leave a comment

ESMO abstracts are available

The following are the abstracts I was able to find. I suspect there are more. RXDX abstract – 19 patients tested at different dose levels, 7 responded https://www.webges.com/cslide/library/esmo/browse/search/88R#9f9C0382 Alectinib Japanese trial, 28 pretreated with Crizotinib. Response rate was 58.3% https://www.webges.com/cslide/library/esmo/browse/search/jZ#9f9v … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, RXDX-101 - entrectinib - by Ignyta | Leave a comment